MicroSectors FANG and Innovation 3X Leveraged ETN vs Immunovant Inc. Common Stock — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.61 (market cap $2.98B), while Immunovant Inc. Common Stock trades at $30.25 (market cap $6.25B). The key difference: Immunovant Inc. Common Stock is far larger — about 2.1× MicroSectors FANG and Innovation 3X Leveraged ETN's market cap, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and Immunovant Inc. Common Stock for 0 Days on average.
| FNGU | IMVT | |
|---|---|---|
Market Cap | $2.98B | $6.25B |
Volume | 4,682,352 | 1,755,411 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $44.96 |
52-Week Low | $13.73 | $17.03 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | — | $5.35B |
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3X leveraged ETN tracking major tech stocks, trades at $37.20 with a 1.92% daily gain. Technical indicators show strong bullish momentum with moving averages unanimously positive, though RSI levels suggest potential overbought conditions. The ETN faces significant volatility risks given its leveraged structure and concentration in top AI and tech names.
While the bullish technical setup and exposure to market-leading tech stocks present short-term upside potential, FNGU carries substantial risk from its triple leverage and historical volatility. Investors should be cautious of rapid drawdowns similar to the 87% decline experienced during previous tech sector corrections.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →